We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus.
- Authors
Amanat, Fatima; Strohmeier, Shirin; Meade, Philip; Dambrauskas, Nicholas; Mühlemann, Barbara; Smith, Derek J.; Vigdorovich, Vladimir; Sather, D. Noah; Coughlan, Lynda; Krammer, Florian
- Abstract
Vaccines against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have been highly efficient in protecting against Coronavirus Disease 2019 (COVID-19). However, the emergence of viral variants that are more transmissible and, in some cases, escape from neutralizing antibody responses has raised concerns. Here, we evaluated recombinant protein spike antigens derived from wild-type SARS-CoV-2 and from variants B.1.1.7, B.1.351, and P.1 for their immunogenicity and protective effect in vivo against challenge with wild-type SARS-CoV-2 in the mouse model. All proteins induced high neutralizing antibodies against the respective viruses but also induced high cross-neutralizing antibody responses. The decline in neutralizing titers between variants was moderate, with B.1.1.7-vaccinated animals having a maximum fold reduction of 4.8 against B.1.351 virus. P.1 induced the most cross-reactive antibody responses but was also the least immunogenic in terms of homologous neutralization titers. However, all antigens protected from challenge with wild-type SARS-CoV-2 in a mouse model. This study explores the immune response induced by wild type and variant SARS-CoV-2 spike proteins, and the protection that these immune responses provide against challenge with wild type virus in the mouse model.
- Subjects
COVID-19; CORONAVIRUSES; IMMUNOGLOBULINS; SARS-CoV-2; RECOMBINANT proteins; VACCINATION; ANTIBODY formation; VIRUSES
- Publication
PLoS Biology, 2021, Vol 19, Issue 12, p1
- ISSN
1544-9173
- Publication type
Article
- DOI
10.1371/journal.pbio.3001384